Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

Four year immunogenicity of the RTS,S/AS02 A malaria vaccine in Mozambican children during a phase IIb trial

Aide, Pedro, Dobano, Carlota, Sacarlal, Jahit, Aponte, John J., Mandomando, Inacio, Guinovart, Caterina, Bassat, Quique, Renom, Montse, Puyol, Laura, Macete, Eusebio, Herreros, Esperanza, Leach, Amanda J., Dubois, Marie-Claude, Demoitie, Marie-Ange, Lievens, MArc, Vekemans, Johan, Loucq, Christian, Ballou, W. Ripley, Cohen, Joe and Alonso, Pedro L. (2011). Four year immunogenicity of the RTS,S/AS02 A malaria vaccine in Mozambican children during a phase IIb trial. Vaccine,29(35):6059-6067.

Document type: Journal Article

IRMA ID 75039815xPUB411
Title Four year immunogenicity of the RTS,S/AS02 A malaria vaccine in Mozambican children during a phase IIb trial
Author Aide, Pedro
Dobano, Carlota
Sacarlal, Jahit
Aponte, John J.
Mandomando, Inacio
Guinovart, Caterina
Bassat, Quique
Renom, Montse
Puyol, Laura
Macete, Eusebio
Herreros, Esperanza
Leach, Amanda J.
Dubois, Marie-Claude
Demoitie, Marie-Ange
Lievens, MArc
Vekemans, Johan
Loucq, Christian
Ballou, W. Ripley
Cohen, Joe
Alonso, Pedro L.
Journal Name Vaccine
Publication Date 2011
Volume Number 29
Issue Number 35
ISSN 0264-410X   (check CDU catalogue  open catalogue search in new window)
Scopus ID 2-s2.0-79960710582
Start Page 6059
End Page 6067
Total Pages 8
Place of Publication United Kingdom
Publisher Elsevier Ltd
HERDC Category C1 - Journal Article (DIISR)
Abstract Previous studies with the malaria vaccine RTS,S/AS02(A) in young children in a malaria endemic area of Mozambique have shown it to have a promising safety profile and to reduce the risk of Plasmodium falciparum infection and disease. In this study, we assessed the antibody responses to the P. falciparum and hepatitis B components of the RTS,S/AS02(A) vaccine over a 45 months surveillance period in a large phase IIb trial which included 2022 children aged 1-4 years at recruitment. The RTS,S/AS02(A) vaccine induced high anti-circumsporozoite antibody levels with at least 96% of children remaining seropositive during the entire follow-up period. IgG titers decayed over the first 6 months of follow-up to about 25% of the initial level, but still remained 30-fold higher until month 45 compared to controls. Children with higher levels of naturally acquired immunity at baseline, assessed by blood stage indirect fluorescent antibody test, had slightly higher anti-circumsporozoite levels, after adjusting for the effect of age. The RTS,S/AS02(A) vaccine also induced high levels of anti-hepatitis B surface antigen antibodies (seroprotection >97%). RTS,S/AS02(A) vaccine is immunogenic and induces long-lasting anti-circumsporozoite antibodies, persisting at least 42 months after immunization. These antibodies may play a role in protection against malaria.
Keywords RTS
S/AS02A
Malaria
Vaccine
Immunogenicity
Children
DOI http://dx.doi.org/10.1016/j.vaccine.2011.03.041   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
 
Versions
Version Filter Type
Access Statistics: 6 Abstract Views  -  Detailed Statistics
Created: Tue, 24 Feb 2015, 12:34:32 CST